Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic ...
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis - Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European Academy of Dermatology and Venereology ( …